alirocumab
regeneron
['alirocumab']
odyssey outcomes analysis presented today . baseline lp(a) predicts revascularisation. importantly, benefit of alirocumab in reducing revascularization appeared confined to patients with elevated lp(a), despite similar baseline and achieved ldl-c across quartiles 1/2 
??????